Chemomab Therapeutics Ltd. (CMMB)
| Market Cap | 12.20M +95.0% |
| Revenue (ttm) | n/a |
| Net Income | -9.00M |
| EPS | -1.41 |
| Shares Out | 7.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 440 |
| Open | 1.720 |
| Previous Close | 1.700 |
| Day's Range | 1.700 - 1.720 |
| 52-Week Range | 1.350 - 5.880 |
| Beta | 0.51 |
| Analysts | Buy |
| Price Target | 25.00 (+1,374.93%) |
| Earnings Date | May 14, 2026 |
About CMMB
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and i... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for CMMB stock is "Buy" and the 12-month stock price target is $25.0.
News
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
—New C linical and Translational Data Presented at Major Medical Meetings Further Confirms the Disease-Modifying Potential of Nebokitug in Primary Sclerosing Cholangitis and Suggests Possible Addition...
Chemomab Therapeutics sees cash runway through 1Q27
Cash, cash equivalents and short-term bank deposits were $10.4 million as of December 31, 2025 compared to $14.3 million as of December 31, 2024. The current cash runway is expected…
Chemomab Therapeutics reports FY25 EPS (1c) vs. (4c) last year
“2025 was a critical year for Chemomab and our nebokitug program,” said Adi Mor, PhD, co-founder and Chief Executive Officer of Chemomab. “Our Phase 2 SPRING trial data, viewed by…
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
2025 was a critical year for Chemomab and nebokitug. Partnering discussions continue to advance along with preparations to launch the PSC Phase 3 trial.
Chemomab Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Nebokitug, a first-in-class antibody targeting CCL24, has shown strong anti-inflammatory and anti-fibrotic effects in PSC, with phase II data supporting an upcoming phase III trial focused on moderate to advanced disease. The company is seeking partners and has funding secured through 2026.
Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
TEL AVIV, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammato...
Chemomab Therapeutics announces results of its Phase 2 SPRING trial
Chemomab Therapeutics (CMMB) announced that the results of its Phase 2 SPRING trial assessing nebokitug in patients with primary sclerosing cholangitis, PSC, were published in the current issue of the...
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
— New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifying Potential of Nebokitug in PSC and Supports Advancement to a P hase 3 Registration Trial — TEL AVIV...
Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit
TEL AVIV, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammato...
Chemomab Therapeutics reports Q3 EPS (0.4c) vs (1c) last year
“In the third quarter of 2025 we focused on advancing preparations for the nebokitug Phase 3 trial in patients with primary sclerosing cholangitis, continuing our very productive discussions with the…
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
—Nebokitug PSC Phase 3 Design Near Completion Following Positive FDA Feedback— —Regulatory Alignment Advances, with EMA Guidance Supporting a Single Nebokitug Phase 3 Registration Trial Using a Clinic...
Chemomab announces presentations at AASLD 2025 on nebokitug data
Chemomab Therapeutics (CMMB) announced that abstracts that highlight new clinical data from the nebokitug Phase 2 SPRING trial in primary sclerosing cholangitis, PSC, will be presented on November 10,...
Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
Chemomab announced three presentations "of distinction" at AASLD The Liver Meeting® 2025 featuring clinical data from the nebokitug Phase 2 trial in PSC.
Chemomab Therapeutics management to meet with Maxim
Meeting to be held on September 15-16 hosted by Maxim.
Chemomab Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Positive phase II results for nebokitug in PSC showed strong anti-inflammatory and anti-fibrotic effects, with FDA alignment for a single pivotal phase III study. The drug is positioned as a potential first-in-class, disease-modifying therapy with significant commercial potential.
Chemomab Therapeutics price target raised to $25 from $10 at Oppenheimer
Oppenheimer raised the firm’s price target on Chemomab Therapeutics (CMMB) to $25 from $10 and keeps an Outperform rating on the shares to reflect Q2 results and management’s intent to…
Chemomab Therapeutics Ltd – ADR trading halted, news pending
19:50 EDT Chemomab Therapeutics (CMMB) Ltd – ADR trading halted, news pending
Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
TEL AVIV, Israel, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammato...
Chemomab Therapeutics reports Q2 EPS 0.4c vs 0.013c last year
“In the second quarter of 2025 Chemomab continued to lay the groundwork for the nebokitug Phase 3 program in primary sclerosing cholangitis and to progress discussions with potential strategic collabo...
Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
— Phase 3 Preparations Ongoing as Company Continues to Advance Multiple Partnering Options for Executing the Nebokitug Phase 3 Program— —Phase 2 SPRING Trial Data Highlighting Nebokitug's Unique Anti-...
Chemomab Therapeutics management to meet with Maxim
Meeting to be held on August 7-8 hosted by Maxim.
Chemomab Therapeutics announces data from Phase 2 SPRING trial of nebokitug
Chemomab Therapeutics (CMMB) announced that data from the company’s Phase 2 SPRING trial of nebokitug in patients with primary sclerosing cholangitis, PSC, was presented in an oral session1 at BSG…
Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25
SPRING Trial Data Presented at BSG Live'25 Confirms the Clinical Potential of Nebokitug as a First-in-Class Novel Treatment for PSC and Supports Advancement to Phase 3 Treatment with Nebokitug Is Well...
Chemomab obtained feedback from two recent FDA meetings on nebokitug
Chemomab Therapeutics (CMMB) reported that it has obtained confirmation from the FDA on two significant development milestones as the company continues to finalize the nebokitug Phase 3 program. As pa...
Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis
—Achieves FDA Alignment on CMC and Non-Clinical Toxicology Regulatory Path for Nebokitug in PSC— —Preparations for the Nebokitug PSC Phase 3 Clinical Trial Advance as Discussions with Potential Strate...